[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346517-105":59,"doc-detail-346517-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","neoadjuvant-immune-checkpoint-inhibitors-for-localized-dmmrmsi-h-gastric-cancer-a-meta-analysis","Neoadjuvant immune checkpoint inhibitors for localized dMMR/MSI-H gastric cancer - a meta-analysis","","Neoadjuvant immune checkpoint inhibitors (ICIs) show high tumor regression rates in localized deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) gastric and gastroesophageal junction (GEJ) cancers, but evidence is limited by small, nonrandomized cohorts. A systematic review searched major databases through June 2025 and included prospective or retrospective neoadjuvant ICI studies reporting prespecified outcomes. Twenty studies with 396 patients were synthesized, estimating pooled pCR and response rates and summarizing nonoperative management safety signals and immune-related adverse events.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/neoadjuvant-immune-checkpoint-inhibitors-for-localized-dmmrmsi-h-gastric-cancer-a-meta-analysis/346517/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/neoadjuvant-immune-checkpoint-inhibitors-for-localized-dmmrmsi-h-gastric-cancer-a-meta-analysis/346517.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main question addressed by the meta-analysis?","Question",{"text":112,"@type":113},"The meta-analysis evaluates efficacy and safety of neoadjuvant immune checkpoint inhibitors for localized dMMR/MSI-H gastric and GEJ cancers, including interest in nonoperative management.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were outcomes and study quality assessed?",{"text":117,"@type":113},"Researchers searched PubMed, EMBASE, Scopus, Web of Science, and Cochrane Reviews up to June 2025, extracted data independently by two reviewers, and assessed quality using PRISMA-guided methods.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes were pooled across included studies?",{"text":121,"@type":113},"Across 20 studies (396 patients), pooled rates included pathologic complete response (pCR) of 41.9% and clinical complete response of 63.8%, alongside estimates of major pathologic response and grade 3–4 immune-related adverse events.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346517,1790176297,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","REVIEW  \nNeoadjuvant immune checkpoint inhibitors for localized dMMR/MSI-H gastric cancer: a meta-analysis  \nW. K. Schwengber1 ∗, R. A. Pereira2, L. F. Leite da Silva3, M. Tumelero4, G. Lenz5, I. Michelon6, K. Chung1,  \nP. L. S. Uson Junior 7,8, T. Bekaii-Saab8 , [C. de](C. de) la Fouchardière9 & M. B. Sonbol 8  \n1Internal Medicine Division, Mayo Clinic, Phoenix, USA; 2Medicine Division, Hospital Santa Casa, Sao Jose dos Campos, São Paulo; 3Department of Medical Sciences, Federal Fluminense University, Rio de Janeiro; 4Department of Medicine, UNOESC University, Joaçaba, SC, Brazil; 5Internal Medicine, AdventHealth, Orlando; 6Department of Hematology/Oncology, University of Virginia, Charlottesville, USA; 7Center for Personalized Medicine, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; 8Mayo Clinic Cancer Center, Phoenix, USA; 9Institut PAOLI-CALMETTES, Marseille, France  \nAvailable online xxx  \nBackground: Early studies indicate that neoadjuvant immune checkpoint inhibitors (ICIs) induce high rates of tumor regression in localized deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) gastric and gastroesophageal junction (GEJ) cancers, raising interest in nonoperative management (NOM) . Most available data, however, come from small, nonrandomized cohorts. A systematic synthesis was undertaken to better characterize efficacy and safety outcomes.  \nMaterials and methods: A systematic search of PubMed, EMBASE, Scopus, Web of Science, and Cochrane Reviews was conducted from inception through June 2025 for prospective or retrospective studies of neoadjuvant ICIs in localized dMMR/MSI-H gastric or GEJ cancers reporting at least one prespecified outcome. Two reviewers independently extracted data and assessed study quality according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Pooled estimates were calculated using a DerSimonian and Laird randomeffects model, and NOM outcomes were qualitatively summarized.  \nResults: Twenty studies (396 patients) met inclusion criteria; three used dual ICI therapy, and the remainder used ICI alone or with chemotherapy. Overall, 320 patients (81 .0%) underwent surgical resection. The pooled pathologic complete response (pCR) rate was 41.9%[95% confidence interval (CI) 33. 2% to 51. 1%], clinical complete response 63.8% (95% CI 45.6% to 78.8%), major pathologic response 64. 2% (95% CI 49. 1% to 76.9%), and grade 3-4 immune-related adverse events 6.7%(95% CI 1.7% to 13.8%) . pCR was higher with treatment duration ≥3 months compared with \u003C3 months [50 . 2%(95% CI 42.3% to 58.7%) versus 28.4%(95% CI 18.9% to 40. 2%), χ2 = 8.84, P = 0.003] . Forty-four patients were managed nonoperatively, with two early local regrowths at median follow-up ranging from 11.5 to 28 months.  \nConclusions: Neoadjuvant ICIs are associated with favorable efficacy and safety in localized dMMR/MSI-H gastric and GEJ cancers. Longer neoadjuvant exposure (≥3 months) may improve pCR rates. Larger prospective studies are needed to define optimal treatment duration and the role of organ-preserving strategies such as NOM.  \nKey words: immune checkpoint inhibitors, neoadjuvant therapy, microsatellite instability-high, deficient mismatch repair, gastric cancer  \nINTRODUCTION  \nPerioperative chemotherapy followed by surgery is the standard of care for resectable gastric and gastroesophageal junction (GEJ) cancers.1-3 The prevalence of deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) in  \n*Correspondence to: Dr Wallace Klein Schwengber, 13400 E Shea Blvd, Scottsdale, AZ 85259-5452, USA. Tel: +1-480-301-8000  \nE-mail: [kleinschwengber.wallace@mayo.edu](kleinschwengber.wallace@mayo.edu) (W. K. Schwengber).  \n2059-7029/© 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creati","cbCaibKEZIaLi4cw","https://ap.wps.com/l/cbCaibKEZIaLi4cw","pdf",1086973,"English","# Review\n## Background\n## Materials and methods\n## Results\n## Conclusions\n## Introduction\n## Evidence from early-phase trials","[{\"question\":\"What is the main question addressed by the meta-analysis?\",\"answer\":\"The meta-analysis evaluates efficacy and safety of neoadjuvant immune checkpoint inhibitors for localized dMMR/MSI-H gastric and GEJ cancers, including interest in nonoperative management.\"},{\"question\":\"How were outcomes and study quality assessed?\",\"answer\":\"Researchers searched PubMed, EMBASE, Scopus, Web of Science, and Cochrane Reviews up to June 2025, extracted data independently by two reviewers, and assessed quality using PRISMA-guided methods.\"},{\"question\":\"What outcomes were pooled across included studies?\",\"answer\":\"Across 20 studies (396 patients), pooled rates included pathologic complete response (pCR) of 41.9% and clinical complete response of 63.8%, alongside estimates of major pathologic response and grade 3–4 immune-related adverse events.\"}]","Neoadjuvant immune checkpoint inhibitors for localized dMMR/MSI-H gastric cancer - a meta-analysis | PDF",1790061787,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c89b36964145cb0f830af55028d89198.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2717bd39133aa7219bebcf5be4a0a3b5.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2cbebcd5266562f32ed4ef3093cb79ae.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e7b82f7516b47e61999f5fb2bfbada9.webp",980,1265]